Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLM101 open-label extension in PMM2-CDG
2024-512171-12-00Phase 2Authorised
- Sponsor
- Glycomine
- Start
- Sep 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of GLM101 in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), sponsored by Glycomine. Primary endpoint: Safety and tolerability. Planned start Sep 2024; status: authorised.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on 2024-512171-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512171-12-00.